Novel, low potency CB2
receptor silent antagonist and CB1
receptor partial inverse agonist. Competitively antagonizes effects of CP 55,940 (pA2
= 6.1) and SR 144528 (pEC50
= 5.3) at CB2
receptors and acts as a partial inverse agonist at CB1
= 5.5). Displays modest activity at human melatonin MT1
and muscarinic M4
receptors, but is selective over several other GPCRs.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Other Product-Specific Information:
Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.
Savinainen et al.
The citations listed below are publications that use Tocris products. Selected citations for WIN 55,212-3 mesylate include:
Showing Results 1 - 1 of 1